| Authors: |
Piperno-Neumann S; Institut Curie, Paris, France. sophie.piperno-neumann@curie.fr., Carlino MS; Blacktown and Westmead Hospitals, Sydney, NSW, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Boni V; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Loirat D; Institut Curie, Paris, France., Speetjens FM; Leiden University Medical Center, Leiden, The Netherlands., Park JJ; Blacktown and Westmead Hospitals, Sydney, NSW, Australia., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Carvajal RD; Columbia University Irving Medical Center, New York, NY, USA., Nyakas M; Oslo University Hospital, Oslo, Norway., Gonzalez-Maffe J; Novartis Pharma AG, Basel, Switzerland., Zhu X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Shirley MD; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ramkumar T; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Fessehatsion A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Burks HE; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Yerramilli-Rao P; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Kapiteijn E; Leiden University Medical Center, Leiden, The Netherlands. |
